Biotech stocks surge as investors anticipate buyouts

Over the last six weeks the U.S. Biotech Index has shot up [1] 13 percent, a clear indication that investors are hungrily anticipating a round of buyouts in the drug discovery business. Pfizer, of course, remains the big hunter [2] in this game, with CEO Jeffrey Kindler (photo [3]) considered a likely candidate to use a marquee-name deal to mark his rise to the top of that troubled pharma giant. But a whole range of Big Pharma companies are expected to weigh in on the bidding list, with the possible exception of a troubled Merck. Biogen Idec [4] and ImClone Systems [5] are at the top of the target list, especially as Biogen Idec has planted a 'for sale' sign on the company's door.

- read the article [6] from The Wall Street Journal (sub. req.)

Related Articles:
Repeat after me: Stock prices will grow in autumn. Report [1]
Biotech lags Pharma stocks in first half of 2007. Report [7]
Pfizer kills off Exubera, hunts for deals. Report [8]
Biogen Idec in play after Icahn makes his move. Report [9]
Speculation soars over Pfizer's interest in biotech. Report [10]